Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.
Phase 1
Completed
- Conditions
- Bacterial InfectionsHIV Infections
- Registration Number
- NCT00002139
- Lead Sponsor
- Pfizer
- Brief Summary
To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.
- Detailed Description
Patients are randomized to receive azithromycin orally or intravenously, with crossover to the alternate treatment after a 21-day wash-out period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of azithromycin uptake in HIV-infected white blood cells?
How does azithromycin pharmacokinetics in buffy coat compare to standard-of-care antibiotics for HIV-related bacterial infections?
Which biomarkers correlate with azithromycin efficacy in HIV-infected patients with bacterial co-infections?
What adverse events are associated with azithromycin in HIV patients and how are they managed?
Are there synergistic effects of azithromycin with antiretroviral therapies in HIV treatment regimens?
Trial Locations
- Locations (1)
Ctr for Phase I Research
🇺🇸Wichita, Kansas, United States
Ctr for Phase I Research🇺🇸Wichita, Kansas, United States